<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/18/bioxcel-therapeutics-nasdaqbtai-stock-price-up-11-1.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-18T16:25:54+00:00"/>
    <meta property="og:title" content="BioXcel Therapeutics (NASDAQ:BTAI) Stock Price Up 11.1%"/>
    <meta property="og:description" content="BioXcel Therapeutics Inc (NASDAQ:BTAI)’s share price rose 11.1% on Monday . The company traded as high as $5.25 and last traded at $5.72, approximately 22,632 shares traded hands during mid-day trading. A decline of 72% from the average daily volume of 80,189 shares. The stock had previously closed at $5.15. BTAI has been the subject […]"/>
  </head>
  <body>
    <article>
      <h1>BioXcel Therapeutics (NASDAQ:BTAI) Stock Price Up 11.1%</h1>
      <address><time datetime="2019-11-18T16:25:54+00:00">18 Nov 2019, 16:25</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/bioxcel-therapeutics-inc-logo.png"/>
      </figure>
      <p>BioXcel Therapeutics Inc (NASDAQ:BTAI)’s share price rose 11.1% on Monday . The company traded as high as $5.25 and last traded at $5.72, approximately 22,632 shares traded hands during mid-day trading. A decline of 72% from the average daily volume of 80,189 shares. The stock had previously closed at $5.15.</p>
      <p>BTAI has been the subject of a number of recent analyst reports. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=BTAI">ValuEngine</a> raised BioXcel Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> raised BioXcel Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, September 11th. BMO Capital Markets set a $21.00 price objective on BioXcel Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, September 18th. SunTrust Banks initiated coverage on BioXcel Therapeutics in a research report on Tuesday, November 12th. They issued a “buy” rating and a $24.00 price objective for the company. Finally, HC Wainwright set a $25.00 price objective on BioXcel Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $20.60.</p>
      <p>The stock has a 50-day simple moving average of $5.44 and a 200 day simple moving average of $9.14. The company has a current ratio of 3.93, a quick ratio of 3.93 and a debt-to-equity ratio of 0.04. The company has a market cap of $68.59 million, a price-to-earnings ratio of -4.39 and a beta of 2.80.</p>
      <p>BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings results on Thursday, November 14th. The company reported ($0.57) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.02. As a group, research analysts forecast that BioXcel Therapeutics Inc will post -2.3 EPS for the current fiscal year.</p>
      <p>In other news, Director Peter Mueller purchased 8,446 shares of the stock in a transaction on Thursday, August 22nd. The stock was bought at an average price of $8.74 per share, with a total value of $73,818.04. The purchase was disclosed in a legal filing with the SEC, which is accessible through <a href="https://www.sec.gov/Archives/edgar/data/1256126/000110465919047150/a4.xml">the SEC website</a>. Insiders own 64.80% of the company’s stock.</p>
      <p>Several hedge funds have recently modified their holdings of the company. Capital Investment Advisory Services LLC acquired a new position in shares of BioXcel Therapeutics in the 2nd quarter valued at about $53,000. Rational Advisors LLC acquired a new position in shares of BioXcel Therapeutics in the 3rd quarter valued at about $48,000. Strs Ohio lifted its holdings in shares of BioXcel Therapeutics by 431.3% in the 3rd quarter. Strs Ohio now owns 8,500 shares of the company’s stock valued at $59,000 after buying an additional 6,900 shares during the period. Artemis Investment Management LLP lifted its holdings in shares of BioXcel Therapeutics by 1.0% in the 2nd quarter. Artemis Investment Management LLP now owns 979,015 shares of the company’s stock valued at $10,644,000 after buying an additional 10,036 shares during the period. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of BioXcel Therapeutics in the 2nd quarter valued at about $138,000. 20.66% of the stock is owned by institutional investors and hedge funds.</p>
      <p><b>About BioXcel Therapeutics</b> (<a href="https://www.marketbeat.com/stocks/NASDAQ/BTAI/">NASDAQ:BTAI</a>)</p>
      <p>BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.</p>
      <p>Featured Story: <a href="https://www.marketbeat.com/financial-terms/understanding-market-liquidity/">Understanding Market Liquidity</a></p>
    </article>
  </body>
</html>